iX Biopharma Ltd

Core Technology

At the heart of iX Biopharma's business is its proprietary sublingual delivery platform known as WaferiX. This technology is a fast-dissolving wafer formulation designed to deliver drugs sublingually. The WaferiX platform offers several advantages over conventional oral dosage forms, including rapid onset of action, improved bioavailability, avoidance of first-pass metabolism in the liver, and ease of administration for patients who may have difficulty swallowing tablets or capsules.

The WaferiX platform underpins much of the company's pharmaceutical development work and represents a versatile drug delivery system that can be applied across a range of therapeutic areas, including pain management, mental health, and men's health.

Pharmaceutical Products and Pipeline

Wafermine

Wafermine is one of iX Biopharma's flagship pharmaceutical candidates. It is a sublingual formulation of ketamine developed using the WaferiX platform and is being investigated as a treatment for acute pain and chronic pain conditions. By delivering ketamine sublingually, Wafermine aims to provide effective, non-opioid pain relief with a rapid onset, addressing the growing need for alternatives to opioid-based analgesics.

Wafesil

Wafesil is a sublingual wafer formulation of sildenafil, the active ingredient used in the treatment of erectile dysfunction. Utilising the WaferiX delivery system, Wafesil is designed to offer faster onset compared to conventional oral sildenafil tablets, providing an alternative option for men seeking treatment for erectile dysfunction.

Xativa

Xativa is a sublingual medicinal cannabis product developed by the company. It represents iX Biopharma's entry into the medicinal cannabis space, again leveraging the sublingual wafer technology to deliver cannabinoids for therapeutic purposes.

Nutraceutical and Consumer Health Products

Beyond its pharmaceutical pipeline, iX Biopharma has developed a portfolio of nutraceutical and consumer health products marketed under the brand Entity Health. These products extend the company's expertise in delivery and formulation into the wellness and dietary supplement sectors.

Entity Health

Entity Health is the company's consumer-facing brand offering a range of nutraceutical products aimed at supporting general health and wellbeing. The product line includes supplements formulated to address areas such as sleep, cognitive health, immunity, and overall vitality. These products allow the company to generate revenue from the growing global market for dietary supplements and functional health products while its pharmaceutical candidates progress through development and regulatory pathways.

Manufacturing Operations

iX Biopharma operates manufacturing facilities designed to meet international quality and regulatory standards, including Good Manufacturing Practice (GMP) requirements. Its manufacturing capabilities support both the production of its pharmaceutical wafer products and its nutraceutical range. The company's operations in Australia include facilities that enable the cultivation, extraction, and production associated with its medicinal cannabis and pharmaceutical activities, supporting a controlled and integrated supply chain.

Research and Development

Research and development is central to iX Biopharma's strategy. The company invests in the ongoing refinement of its WaferiX platform and the advancement of its clinical-stage drug candidates. Its R&D efforts focus on demonstrating the safety, efficacy, and commercial viability of its products through preclinical studies and clinical trials, with the aim of achieving regulatory approval in key markets.

The company's development programmes address significant unmet medical needs, particularly in the areas of pain management where there is increasing demand for effective non-opioid therapies, and in men's health and mental health where innovative delivery formats can improve patient outcomes and adherence.

Business Strategy

iX Biopharma pursues a dual strategy that combines the long-term value creation potential of its pharmaceutical pipeline with the nearer-term revenue generation of its nutraceutical business. This approach allows the company to build commercial infrastructure and generate cash flow through its consumer health products while advancing higher-value drug candidates through the costly and time-intensive process of clinical development and regulatory approval.

The company also seeks to expand its geographic footprint and pursue partnerships, licensing arrangements, and distribution agreements to commercialise its products across multiple markets. Its sublingual delivery technology serves as a platform that can be applied to a broad range of molecules, offering opportunities for collaboration with other pharmaceutical companies seeking improved delivery formats for their own compounds.

Market Position

As a company listed on the Singapore Exchange, iX Biopharma operates within the growing Asian and global markets for pharmaceuticals and consumer health products. Its focus on sublingual delivery differentiates it within the specialty pharmaceutical landscape, and its work in areas such as non-opioid pain management and medicinal cannabis positions it within therapeutic categories experiencing significant demand and evolving regulatory frameworks.

Summary

iX Biopharma Ltd is a Singapore-based specialty pharmaceutical and nutraceutical company built around its proprietary WaferiX sublingual drug delivery technology. Through pharmaceutical candidates such as Wafermine, Wafesil, and Xativa, alongside its Entity Health consumer nutraceutical brand, the company addresses needs in pain management, men's health, mental health, and general wellness. With integrated research, development, and manufacturing capabilities across Singapore and Australia, iX Biopharma combines innovative drug delivery science with a commercial consumer health business to pursue growth in the pharmaceutical and life sciences sectors.